Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Related Information
Registry Information

Alternate Title

Phase II Study of Cyclosporine in Patients With T-Cell Large Granular Lymphocyte Leukemia

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Biomarker/Laboratory analysis, Treatment	Active	Over 18	NCI	NCI-06-C-0177 NCI-P6830, NCT00363779

Special Category: NIH Clinical Center trial

Trial Description

Purpose:

Drugs used in chemotherapy, such as cyclosporine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Collecting samples of blood to study in the laboratory from patients with cancer who have received cyclosporine may help doctors learn more about changes that may occur in DNA and predict how well patients will respond to cyclosporine.

This phase II trial is studying how well cyclosporine works in treating patients with T-cell large granular lymphocyte leukemia.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• Measurable or evaluable disease
• At least 3 weeks since chemotherapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive cyclosporine by mouth twice a day. Treatment may continue for at least 3 months.

Patients will undergo blood collection periodically for laboratory studies.

After finishing treatment, patients will be evaluated at 1 month and every 3 months thereafter.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

NCI - Center for Cancer Research

John Janik, MD, Principal investigator		Ph: 301-402-2913 Email: janikj@mail.nih.gov

U.S.A.
Maryland
	Bethesda
	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
		Clinical Trials Office - Warren Grant Magnusen Clinical Center - NCI Clinical Trials Referral Office	Ph:  888-NCI-1937

Related Information

Web site for additional information

Registry Information
Official Title		Microarray Analysis of the Effect of Cyclosporin Therapy on Gene Expression in Large Granular Lymphocyte (LGL) Leukemia
Trial Start Date		2006-01-01
Trial Completion Date		2010-12-22 (estimated)
Registered in ClinicalTrials.gov		NCT00363779
Date Submitted to PDQ		2006-06-08
Information Last Verified		2009-07-05

Back to Top